Abstract
Elevated plasma homocysteine (Hcy) concentrations are associated with Alzheimer's disease and vascular dementia. Several recent reports have indicated that L-dopa treatment is an acquired cause of hyperhomo-cysteinemia. Despite the fact that a large proportion of Parkinson's disease (PD) patients develop cognitive dysfunctions or dementia, particularly in the late stages of the illness and after long-term L-dopa treatment, the relationship between Hcy and dementia in PD has not been fully investigated. The aim of this study was to evaluate plasma Hcy levels in a group of L-dopa-treated PD patients with cognitive impairment and to elucidate a possible role of Hcy in the development of cognitive dysfunctions in PD. We compared Hcy, vitamin B12 and folate levels in 35 parkinsonian patients treated with L-dopa (14 with cognitive dysfunctions, 21 without cognitive impairment). Analysis of the data revealed that mean Hcy levels were significantly higher in the group with cognitive dysfunctions (21.2±7.4 vs. 15.8±4.4μmol/L; p=0.0001), while there was no difference in age, sex, B12 and folate levels. In addition, logistic regression analysis showed that the risk of cognitive dysfunction progressively increased according to Hcy levels after correction for age, sex and B-vitamin status (odds ratio, 19.1; 95% CI, 1.5–241.4; p=0.02). Our results raise the possibility of a relationship between Hcy levels and cognitive dysfunctions in this group of L-dopa-treated PD patients. However, prospective studies on large cohorts of patients should be performed to clarify such an association.
References
1. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476–83.10.1056/NEJMoa011613Search in Google Scholar
2. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2:425–8.10.1016/S1474-4422(03)00438-1Search in Google Scholar
3. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drug Ther 2002; 16:391–9.10.1023/A:1022130217463Search in Google Scholar
4. Gallucci M, Zanardo A, De Valentin L, Vianello A. Homocysteine in Alzheimer disease and vascular dementia. Arch Gerontol Geriatr Suppl 2004; 9:195–200.10.1016/j.archger.2004.04.027Search in Google Scholar
5. McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype and risk for stroke, vascular dementia and Alzheimer disease in Northern Ireland. Stroke 2002; 33:2351–6.10.1161/01.STR.0000032550.90046.38Search in Google Scholar
6. Allain P, LeBouil A, Cordillet E, LeQuay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995; 16:527–9.Search in Google Scholar
7. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998; 40:225–7.10.1159/000007984Search in Google Scholar
8. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine and Parkinson's disease. Lancet 1999; 354:126–7.10.1016/S0140-6736(99)01660-8Search in Google Scholar
9. Rogers J, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa. Association with vascular disease. Arch Neurol 2003; 60:59–64.10.1001/archneur.60.1.59Search in Google Scholar PubMed
10. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effects of L-Dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003; 60:1125–9.10.1212/01.WNL.0000055899.24594.8ESearch in Google Scholar PubMed
11. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2000; 55:437–40.10.1212/WNL.55.3.437Search in Google Scholar PubMed
12. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinemia in Parkinson's disease. Acta Neurol Scand 2003; 108:66–7.10.1034/j.1600-0404.2003.00135.xSearch in Google Scholar
13. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levo-dopa and COMT inhibitors on plasma homocysteine in PD patients. Mov Dis 2005; 20:69–72.10.1002/mds.20261Search in Google Scholar
14. Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti S, Mastronardi R, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005; 11:131–3.10.1016/j.parkreldis.2004.07.008Search in Google Scholar
15. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG. Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60:1125–9.10.1212/01.WNL.0000055899.24594.8ESearch in Google Scholar
16. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with levodopa, homocysteine and MTHFR genotype. J Neurol Sci 2003; 207:19–23.10.1016/S0022-510X(02)00353-2Search in Google Scholar
17. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Bottiglieri T, et al. Elevated plasma homocysteine levels in patients with Parkinson's disease. Motor, affective and cognitive associations. Arch Neurol 2004; 61:865–8.10.1001/archneur.61.6.865Search in Google Scholar PubMed
18. Muller T, Renger K. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004; 61:657–60.10.1001/archneur.61.5.657Search in Google Scholar PubMed
19. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19:1403–8.10.1002/mds.20253Search in Google Scholar PubMed
20. Postuma RB, Lang A. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004; 63:886–91.10.1212/01.WNL.0000137886.74175.5ASearch in Google Scholar PubMed
21. Brosnan JT, Jacobs RL, Stead LM, Brosnan ME. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol 2004; 51:405–13.10.18388/abp.2004_3580Search in Google Scholar
22. Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005; 12:365–8.10.1111/j.1468-1331.2004.00973.xSearch in Google Scholar
23. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm Suppl 2004; 68:15–20.10.1007/978-3-7091-0579-5_2Search in Google Scholar
24. Emre R. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2:229–37.10.1016/S1474-4422(03)00351-XSearch in Google Scholar
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427–42.10.1212/WNL.17.5.427Search in Google Scholar
26. Folstein MF, Folstein FE, McHugh POR. Mini-Mental State: a practical method for grading the cognitive state for the clinician. J Psychiatry Res 1975; 12:189–98.10.1016/0022-3956(75)90026-6Search in Google Scholar
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised 3rd ed. Washington, DC: American Psychiatric Association, 1987.Search in Google Scholar
28. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26:137–46.10.1016/S0166-2236(03)00032-8Search in Google Scholar
29. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behaviour in rodents. Neurotoxicology 2005; 26:361–71.10.1016/j.neuro.2005.01.008Search in Google Scholar PubMed
30. Tijattas L, Ortiz DO, Dhivant S, Mitton K, Rogers E, Shea TB. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cells 2004; 3:71–6.10.1111/j.1474-9728.2004.00086.xSearch in Google Scholar PubMed
31. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11:253–6.10.1016/j.parkreldis.2005.01.007Search in Google Scholar PubMed
32. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, et al. Plasma homocysteine and L-dopa metabolism in patients with Parkinson's disease. Clin Chem 2001; 47:1102–4.10.1093/clinchem/47.6.1102Search in Google Scholar
©2005 by Walter de Gruyter Berlin New York
